Abstract:Previous studies demonstrated that Th1 cytokines like IL-2, IL-12 and IFN-γ have initiatory role in alopecia areata (AA) and positive correlation with disease severity. They informed that serum levels of Th17 cytokines, IL-17, IL-22, IL-23 increased in active AA patients and corelated, particularly IL-17, with disease severity. In recent reports it was showed the balance between Th17 and Treg cells is crucial for maintaining tolerance to self-antigens, and an imbalance towards Th17 may contribute to the development of autoimmune diseases like AA. But research on serum Treg markers in AA is limited. It was aimed to investigate whether the Treg cells have a role in the pathogenesis of AA analyzing the serum levels of Treg cytokines IL-35 and TGF-β in the patients with AA. 42 AA patients and 38 healthy controls were enrolled. Patient demographics, clinical data, disease severity assessed by Severity of Alopecia Tool (SALT) scores were recorded. Serum samples were collected and analyzed for TGF-β and IL-35 levels using ELISA kits. The cytokine levels in both groups were statistically compared. Their relation with parameters of demographic and severity of disease was evaluated. The patient and control groups had no statistically significant difference, there was 71.4% males and 28.6% females in patient group, while the control group had 63.2% males and 36.8% females, Severity analysis classified 18 patients with mild AA, 19 with moderate AA, and 5 with alopecia totalis/areata universalis. While TGF-β levels exhibited no significant difference between groups, IL-35 levels were significantly elevated in AA patients (p = 0.002). Logistic regression identified IL-35 as a significant parameter influencing disease status (OR = 1.055). Correlation analysis revealed a weak positive correlation between patient age and IL-35 levels (r = 0.436; p = 0.004). Notably, IL-35 levels displayed a significant decrease in individuals with antinuclear antibody (ANA) positivity. No correlations were identified between cytokine levels and disease severity, prognosis, or disease activity. Elevated IL-35 levels suggest that IL-35 and specific Treg cell subsets can play a role in AA pathogenesis. The nuanced roles of TGF-β and IL-35 highlight the need for comprehensive studies to interpret their implications in the complex immunopathogenesis of AA. These findings open avenues for further research, positioning IL-35 as a prospective target for investigating and potentially intervening in AA pathogenesis.

Relationship of IFN-γ and IL-10 with Alopecia Areata

JAK Inhibitors for the Treatment of Alopecia Areata

Changes and significance of Th1/Th2 and Treg/Th17 cells and their cytokines in patients with alopecia areata

Elucidating the role of T-Reg related cytokines: serum transforming growth factor beta and interleukin-35 in alopecia areata

Evaluation of several immune and inflammatory indicators and their association with alopecia areata

Novel potential therapeutic targets of alopecia areata

Interleukin-15 is a hair follicle immune privilege guardian

Th17/Treg Balance in Peripheral Blood of Patients with Alopecia Areata

Pathogenesis of Alopecia Areata in C3H/He J Mice and DEBR Rats

Regularities of Change Concentrations of Interleukin-17A, Interleukin-2 and Interleukin-10 in the Blood of People with Alopecia Areata before and after Treatment with Platelet-Rich Plasma

Serum interleukin-15 is a marker of alopecia areata severity

487 Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata

Serum Interleukin 17 as a Marker for Alopecia Areata Severity: A Case-Control Study

Deciphering the Complex Immunopathogenesis of Alopecia Areata

Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata

The role of hsa‐miR‐193a‐5p as an important factor for control of inositol in alopecia areata

Evaluation of Serum Inflammatory Markers and Their Relationship to Treatment Response in Alopecia Areata Patients

Efficacy and safety of compound glycyrrhizin combined with topical minoxidil for alopecia areata: a systematic review and meta-analysis of randomized controlled trials

Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds

Selective Expansion of Tregs Using the IL-2 Cytokine Antibody Complex Does Not Reverse Established Alopecia Areata in C3H/HeJ Mice

Identification of Potential Hub Genes in Alopecia Areata